NLR family CARD domain-containing (NLRC) Inhibitors
The NLR family CARD domain-containing (NLRC) proteins are a subgroup of the larger NLR (NOD-like receptor) family, which play a crucial role in the innate immune system. These proteins are characterized by the presence of a caspase recruitment domain (CARD) at their N-terminal. The CARD domain enables NLRC proteins to interact with other molecules involved in inflammatory and apoptotic pathways. NLRC proteins are primarily involved in recognizing pathogens and initiating immune responses, particularly by activating the NF-κB pathway and regulating cytokine production. Mutations or dysregulation in NLRC proteins can lead to various inflammatory diseases and immune disorders. Their study is vital for understanding disease mechanisms and developing targeted therapies for conditions involving the innate immune response.
NLR family CARD domain-containing (NLRC) Inhibitors are a class of chemical compounds specifically designed to decrease the functional activity of NLRC proteins. These inhibitors operate by targeting various biochemical and cellular pathways that are crucial for the proper functioning of NLRC proteins, particularly in the context of immune response and inflammation. Additionally, there has been interest in developing molecules that target specific interactions within the NLRC protein family, such as the formation of inflammasomes, aiming to disrupt protein-protein interactions crucial for NLRC function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tozasertib | 639089-54-6 | sc-358750 sc-358750A | 25 mg 50 mg | $62.00 $87.00 | 4 | |
BAY 61-3606 is a selective inhibitor of Syk, a kinase involved in NLRC signaling pathways. By inhibiting Syk, BAY 61-3606 disrupts the transduction of signals from upstream receptors to NLRC, directly interfering with the protein's activation. | ||||||
PF-06465469 | 1407966-77-1 | sc-480369 | 5 mg | $83.00 | ||
PF-06465469, a selective and potent inhibitor of RIP2 kinase, directly influences NLRC-mediated signaling pathways. By inhibiting RIP2, PF-06465469 disrupts the downstream events that lead to NLRC activation, providing a targeted approach to inhibit the protein's functionality. This compound highlights the intricate interplay between kinases in NLRC signaling and offers a specific strategy for modulating NLRC activity in cellular processes. | ||||||
Bemcentinib | 1037624-75-1 | sc-507363 | 10 mg | $900.00 | ||
R428, also known as BGB324, is a selective inhibitor of AXL, a receptor tyrosine kinase linked to NLRC signaling pathways. By inhibiting AXL, R428 disrupts the transduction of signals from upstream receptors to NLRC, directly interfering with the protein's activation. | ||||||
IKK-2 Inhibitor IV | 507475-17-4 | sc-203083 | 500 µg | $133.00 | 12 | |
TPCA-1 is a selective inhibitor of IKK-2, a kinase involved in NF-κB signaling downstream of NLRC. By inhibiting IKK-2, TPCA-1 disrupts the transduction of signals from NLRC to NF-κB, directly interfering with the protein's downstream effects. This compound illustrates the potential for specific kinase inhibition to modulate NLRC-mediated signaling and provides insights into the intricate regulatory mechanisms governing the protein's involvement in cellular processes. | ||||||
BX 795 | 702675-74-9 | sc-281689 sc-281689A sc-281689C sc-281689B sc-281689D sc-281689E | 2 mg 5 mg 10 mg 25 mg 50 mg 100 mg | $219.00 $273.00 $331.00 $495.00 $882.00 $1489.00 | 5 | |
BX-795 is a PDK1 inhibitor that indirectly influences NLRC by disrupting the PDK1-AKT signaling pathway, which is linked to NLRC activation. Inhibition of PDK1 by BX-795 leads to downstream effects that modulate NLRC function, exemplifying the potential for targeting upstream regulators to indirectly influence NLRC. | ||||||